Clinical Trial

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-01.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT06965452
Lead Sponsor Northwell Health
Conditions Facet Joint Arthropathy, Pain, Osteoarthritis
Enrollment 40 participants
Start Date 2025-08-12
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-19